Dr.  

Yaowei Zhu


Presentations

Ustekinumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Pediatric Patients (>= 6 to <12 year of age): Pharmacokinetics and Immunogenicity Results From CADMUS Jr 09 October 2019 00:00 - 00:00
Pharmacokinetics and Immunogenicity of Guselkumab Through up to 3 Years of Therapy in Patients With Moderate-to-Severe Plaque Psoriasis 09 October 2019 00:00 - 00:00

Abstracts

Ustekinumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Pediatric Patients (>= 6 to <12 year of age): Pharmacokinetics and Immunogenicity Results From CADMUS Jr Psoriasis More
Pharmacokinetics and Immunogenicity of Guselkumab Through up to 3 Years of Therapy in Patients With Moderate-to-Severe Plaque Psoriasis Psoriasis More